etoposide + ifosfamide + methotrexate

The combination of etoposide, ifosfamide, and methotrexate—commonly referred to as the VIM regimen—is a multi-agent chemotherapy protocol used primarily as salvage therapy in patients with non-Hodgkin lymphoma (NHL) who have failed prior treatment regimens. - **Etoposide** is a topoisomerase II inhibitor that induces DNA strand breaks and prevents cell division. - **Ifosfamide** is an alkylating agent that cross-links DNA strands, leading to apoptosis in rapidly dividing cells. - **Methotrexate** is an antimetabolite and antifolate agent that inhibits dihydrofolate reductase, disrupting DNA synthesis and cell replication. This combination has demonstrated efficacy in inducing complete or partial responses in relapsed or refractory NHL patients, with myelotoxicity being the most common adverse effect[1][2][3][5].

Other names

VIM regimen